Maintaining Investments in New Innovation Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1672 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 1672

   To amend title XI of the Social Security Act to protect access to 
                   genetically targeted technologies.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 27, 2025

 Mr. Davis of North Carolina (for himself, Mr. Joyce of Pennsylvania, 
  Mr. Gottheimer, Ms. Tenney, Mr. Yakym, Mr. Morelle, Mr. Hudson, Mr. 
   Bean of Florida, Mrs. Miller-Meeks, Mr. Allen, Ms. Van Duyne, Mr. 
 Peters, Mr. Moore of Utah, and Mr. Crenshaw) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce, and 
  in addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
   To amend title XI of the Social Security Act to protect access to 
                   genetically targeted technologies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Maintaining Investments in New 
Innovation Act''.

SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SINGLE SOURCE DRUG.

    Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) 
is amended--
            (1) in paragraph (1)(A)(ii), by inserting ``(or, in the 
        case of an advanced drug product (as defined in paragraph (4)), 
        11 years)'' after ``7 years''; and
            (2) by adding at the end the following new paragraph:
            ``(4) Advanced drug product defined.--For purposes of 
        paragraph (1)(A)(ii), the term `advanced drug product' means a 
        drug that incorporates or utilizes a genetically targeted 
        technology (as defined in section 529A(c)(2) of the Federal 
        Food, Drug, and Cosmetic Act) that may result in the modulation 
        (including suppression, up-regulation, or activation) of the 
        function of a gene or its associated gene product.''.
                                 <all>